CHK1 inhibitors have been developed for clinical use, principally with the idea that they would be used to enhance killing of tumor cells by cytotoxic drugs or by radiation, via blocking cell cycle checkpoints, especially in p53 deficient cells [23–26]. This evidence concerns the gene CHEK1 and neoplasm.